A Dramatic Progress in New Drug Development Maximizes Patient Benefit
Sign up for free
Listen to this episode and many more. Enjoy the best podcasts on Spreaker!
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
For this edition of The Onco'Zine Brief, recorded during 59th annual meeting of the American Society of Hematology held December 9 to 12, 2017 in Atlanta, Georgia, Peter Hofland and...
show moreIn this interview Hofland and Portillo asks Benner about the many changes at Astellas, the company’s focus and some of the greatest challenges the company faces. They also talk about the definition of personalized medicine, precision medicine and targeted therapies – and the differences of these approaches beyond the typical ‘buzz words’ – and how personalized medicine, is changing the drug development process.
Hofland and Portillo also ask Benner to share his own impression of this years annual meeting ('Real dramatic progress in the development of novel therapeutic drugs designed to maximize the patient benefit...') and what he thinks is the most exciting clinical news presented.
And, finally, Hofland and Portillo talk with Benner about the results of a poster his company presented about the “Economic Burden of Treatment Episodes in Acute Myeloid Leukemia Patients in the U.S.” Which includes new information about the major drivers of economic burden for Acute Myeloid Leukemia Patients and therapeutic strategies needed to deal with this burden.
Information
Author | Peter Hofland |
Organization | Peter Hofland |
Website | - |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company